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ABSTRACT The purpose of this analysis was to determine the prevalence and correlates
of HIV infection among a street-recruited sample of heroin- and cocaine-using men
who have sex with men (MSM). Injection (injecting ≤3 years) and non-injection drug
users (heroin, crack, and/or cocaine use <10 years) between 18 and 40 years of age were
simultaneously street-recruited into two cohort studies in New York City, 2000–2003,
by using identical recruitment techniques. Baseline data collected among young adult
men who either identified as gay/bisexual or reported ever having sex with a man were
used for this analysis. Nonparametric statistics guided interpretation. Of 95 heroin/
cocaine-using MSM, 25.3% tested HIV seropositive with 75% reporting a previous
HIV diagnosis. The majority was black (46%) or Hispanic (44%), and the median age
was 28 years (range 18–40). HIV-seropositive MSM were more likely than seronega-
tives to be older and to have an HIV-seropositive partner but less likely to report current
homelessness, illegal income, heterosexual identity, multiple sex partners, female partners,
and sex for money/drug partners than seronegatives. These data indicate high HIV
prevalence among street-recruited, drug-using MSM compared with other injection
drug use (IDU) subgroups and drug-using MSM; however, lower risk behaviors were
found among HIV seropositives compared with seronegatives. Large-scale studies
among illicit drug-using MSM from more marginalized neighborhoods are warranted. 
KEYWORDS Drug use, HIV, MSM, Sex risk behavior. 
INTRODUCTION 
Men who have sex with men (MSM) have been at the forefront of the HIV epidemic in
the United States, but especially in Northeastern cities, a considerable portion of HIV
infection is related to injection drug use (IDU). The intersection of these risk behaviors
has received relatively limited attention, especially in minority communities where both
behaviors are stigmatized. The extent to which there might be differences in infection
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rates by mode of administration of illicit drug use has also received limited attention in
MSM. Although HIV incidence rates have been declining among injection drug users in
the United States,1,2 some evidence suggests that a similar decline may not be occurring
among IDU men who have sex with men (IDU-MSM).3 However, HIV surveillance
data from 1999 to 2002 suggest that IDU-MSM have lower prevalence rates (5%) of
newly diagnosed HIV cases compared with non–drug-using MSM (60%).4 These data
reflect only information from individuals who actually tested for HIV and may miss
other drug user categories at high risk (e.g., noninjecting heroin, crack cocaine users).
Furthermore, it is estimated that approximately 25% of all HIV-infected individuals in
the United States are underrepresented in these surveillance reports.5 
Populations identified as being difficult to reach through research and prevention
programs include black and Hispanic IDU-MSM and noninjection heroin- and
crack cocaine-using MSM (non–IDU-MSM).6–9 Early HIV research with IDU study
populations has found higher rates of infection among IDU-MSM,10,11 yet little
information exists with respect to sexual and drug use (specifically heroin and/or
cocaine) behaviors and risk for acquiring HIV among black and Hispanic IDU-MSM. 
HIV research among MSM-study populations has recognized the potential for
underrepresentation of black and Hispanic MSM subgroups.7,8,12–15 One reason for
this may be that recruitment methods commonly employed in studies of MSM often
involve sampling from gay-identified venues such as bars, clubs, circuit venues, and
parks.16 While these settings yield sizeable samples of MSM who may use illicit
drugs, they tend to miss non-gay identified and disenfranchised MSM7,8 from drug-use
neighborhoods characterized by high frequency of heroin and crack cocaine use. 
Among the few current studies conducted among illicit drug-using MSM, varying
sampling or recruitment strategies have been employed so that marginalized popula-
tions are better represented. Studies conducted in New York, Chicago, San Francisco,
and Los Angeles, for example, report HIV prevalence rates among IDU-MSM as high
as 40–43%.17 In a seven-city study, HIV prevalence rates among IDU-MSM were
14.5% compared with 6.7% among non–IDU-MSM.18 These prevalence rates are
higher than recent HIV surveillance data4 and higher than estimates for other subpop-
ulations of injection drug users and noninjection drug users sampled during similar
periods (e.g., heterosexual injection drug users and noninjection drug users).1,19,20 
Given the limited reports on the intersection of illicit drug use and MSM, par-
ticularly injection and noninjection heroin and cocaine use, coupled with the few
reports on illicit drug-using MSM of color from more marginalized communities,
we set forth to estimate prevalence and correlates of HIV infection in a street-
recruited sample of predominantly black and Hispanic MSM using heroin and
cocaine in New York City. 
METHODS 
Study Population 
In August 2000, enrollment of an IDU cohort (Hepatitis C Study) and non-IDU
cohort (Harlem Outreach Prevention and Education (HOPE) Study) began in sev-
eral New York City neighborhoods known for illicit drug activity (Lower East Side
Manhattan, South Bronx, Central Brooklyn, and Queens) targeting young, new
injection drug users and noninjection drug users. Eligibility included individuals
between the ages of 15 and 40 years who injected ≤3 years and noninjecting heroin,
crack, and cocaine users of the same age with <10-year histories of illicit drug use.
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Study participants were recruited simultaneously in each neighborhood by using similar
street outreach techniques as described elsewhere.21 Baseline data collected through
March 2004 from both the Hepatitis C (n =71) and HOPE (n =71) studies were
combined for this analysis. The study population was restricted to male participants
who reported ever having sex with a man and/or identified as gay or bisexual. The
study was approved by the Institutional Review Boards of the New York Academy
of Medicine and the New York Blood Center. 
Data Collection 
Eligible and consenting participants underwent a private, structured interview admin-
istered by a trained interviewer. Demographic factors included age, race/ethnicity
(black, Hispanic, white, or other race), sexual identity (gay or bisexual vs. heterosex-
ual), education (≤high school or general equivalency diploma vs. some college or
higher), source of income (any illegal vs. only legal), homelessness at enrollment (yes
vs. no), and drug treatment (ever vs. never). Drug-use variables collected included
injection status (injected drugs in past 2 years vs. never) and current drug used in past
2 months (heroin, crack, cocaine, speedball, methamphetamine, ecstasy). Sexual part-
nerships and behaviors measured over the past 2 months included number of sex
partners, type of sexual partnerships (any female, injection drug user, noninjection
drug user, known HIV positive, exchanging sex for money/drugs, steady and casual
partnerships), and condom use (ever vs. never). Study participants underwent also
blood draws at baseline for serological testing of HIV by using standard criteria. 
Data Analysis 
Frequencies and proportions were calculated to compare sociodemographics, drug
use, and sexual behaviors stratified by HIV serostatus. Chi-square tests were used to
determine bivariate statistical differences. Significant associations between HIV
serostatus and exposure variables of interest were determined by Fisher’s exact
P values <.05 (due to small cell sizes). 
RESULTS 
Of 101 drug-using MSM, 95 had HIV serology results available for analysis with a
prevalence rate of 25.3% (Table 1). Seventy-five percent of the HIV-seropositive
participants had been previously diagnosed with HIV prior to study entry. The
median age of the overall sample was 28 (range 18–40), with HIV-seropositive
persons significantly older than seronegatives (35 vs. 26 years; P< .001). Most sample
was black (46%) and Hispanic (44%) and there were no race/ethnic differences by
HIV serostatus. Compared with seronegative MSM, a larger proportion of HIV-
seropositive MSM self-identified as either gay or bisexual (92% vs. 65%; P < .012).
A smaller proportion of HIV-seropositive MSM reported current homelessness
(13%) and some type of illegal income source (46%) compared with seronegative
MSM (66%; P < .001, and 69%; P < .042, respectively). Many HIV-seropositive
MSM had at least a high school diploma or equivalent (63%) than seronegative
MSM (45%; P < .140). Approximately two thirds of both HIV seropositive and
seronegative MSM reported a history of drug treatment. 
Table 2 summarizes recent drug-use behaviors in association with HIV-seropositive
status. A smaller proportion (25%) of HIV-seropositive MSM reported recent intra-
nasal heroin use compared with seronegative MSM (46%), and approximately
three fourths of both HIV seropositive and seronegative MSM reported recent crack
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and/or cocaine use. Only 9% of the total sample reported having ever used nonin-
jection methamphetamines, which did not differ by HIV serostatus. Many MSM
reported a history of ecstasy use (20%) with a significantly smaller proportion of
HIV-seropositive MSM reporting use (4%) compared with seronegative MSM
(25%; P < .036). Twenty-five percent of the sample injected drugs, with the majority
injecting heroin (92%) and/or cocaine (75%). One participant reported ever having
injected methamphetamine or some other form of speed. A smaller proportion of
HIV-seropositive MSM (13%) reported ever injecting drugs compared with seronega-
tive MSM (30%; P< .097); contrary to what would be expected. HIV prevalence was
notably higher among non–IDU-MSM (29.6%) compared with IDU-MSM (12.5%). 
For sexual partnerships and behaviors that occurred over the past 2 months
(Table 3), a smaller proportion of HIV-seropositive MSM reported ≥3 sex partners
(38% vs. 65%; P < .020), having any female sex partners (8% vs. 63%; P < .001),
and having an IDU sex partner (12% vs. 25%; P< .190) compared with seronegative
MSM. Having a non-IDU sex partner was common in this sample of drug-using
MSM (67%) regardless of HIV serostatus. HIV-seropositive MSM reported not
being sexually active (17% vs. 10%) or having a steady partner (29% vs. 10%)
more often than seronegative MSM. Similar proportions of HIV seropositive and
seronegative MSM reported having a casual partner only (25% vs. 23%); however,
TABLE 1. Sociodemographic characteristics associated with HIV-seropositive status among 
young adult heroin- and cocaine-using men who have sex with men (MSM) in New York 
City, 2000–2003 




Total (n = 95) 
N (%) 
HIV seropositive 
(n =24) N (%) 
HIV seronegative 
(n = 71) N (%) 
Fisher’s exact 
P value 
Self-identity     
Gay or bisexual 68 (72) 22 (92) 46 (65)  
Heterosexual 27 (28) 2 (8) 25 (35) <.012 
Race     
Hispanic 42 (44) 10 (42) 32 (45)  
Black 44 (46) 14 (58) 30 (42)  
White/other 9 (10) 0 (0) 9 (13) <.130 
Median age (range) 28 (18–40) 35 (19–40) 26 (18–40) <.001 
Education     
<High school 48 (51) 9 (37) 39 (55)  
≥High school/general 
equivalency diploma 47 (49) 15 (63) 32 (45) <.140 
Current homelessness*     
No 45 (47) 21 (87) 24 (34)  
Yes 50 (53) 3 (13) 47 (66) <.001 
Any illegal income†     
No 35 (37) 13 (54) 22 (31)  
Yes 60 (63) 11 (46) 49 (69) <.042 
Drug treatment     
Never 33 (35) 8 (33) 25 (35)  
Ever 62 (65) 16 (67) 46 (65) <0.868 
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fewer HIV seropositives reported having both steady and casual partner types (29%
vs. 57%; P< .055), respectively. Significantly fewer HIV-seropositive MSM reported
having a sex partner with whom they exchanged sex for money/drugs (42%) compared
with seronegative MSM (73%; P< .006). Finally, having a known HIV-seropositive
sex partner was more common among HIV-seropositive MSM compared with
seronegatives (33% vs. 3%; P < .001). 
DISCUSSION 
The major finding of this study was that among this street-recruited population
of young adult non-IDU-MSM and IDU-MSM in New York City, a high HIV
prevalence rate was observed relative to other studies of illicit drug users1,19,22,23
(ranging from 3 to 14%) and MSM8,9,17,18,24 (ranging from 3 to 21%) and yet, sev-
eral sexual risk behaviors demonstrated an inverse association with HIV-seropositive
status. Specifically, HIV-seropositive MSM were less likely to report multiple sex
partners, exchange-for-sex partnerships, and female partnerships compared with
seronegative MSM, behaviors that have been previously suggested as high-risk
among illicit drug users and/or drug-using MSM.25–28 Additionally, HIV-seroposi-
tive MSM tended to report a higher level of socioeconomic status compared with
seronegative MSM. This may seem paradoxical; however, there is a plausible expla-
nation for these findings that is supported by previous reports and various aspects
of this study. 
TABLE 2. Drug-use behaviors associated with HIV-seropositive status among young adult 
heroin-, crack-, and/or cocaine-using men who have sex with men (MSM) in New York 
City, 2000–2003 
*Past 2 months. 
†Majority injected heroin (92%) and/or cocaine (75%); only one reported injecting methamphetamines. 
Drug-use behaviors 
Total (N =95) 
[n (%)] 
HIV seropositive 
(N =24) [n (%)] 
HIV seronegative 
(N =71) [n (%)] 
Fisher’s exact 
P value 
Intranasal heroin use*     
No 56 (59) 18 (75) 38 (54)  
Yes 39 (41) 6 (25) 33 (46) <.064 
Intranasal cocaine use*     
No 2 (22) 7 (29) 14 (20)  
Yes 74 (78) 17 (71) 57 (80) <.335 
Smoke crack*     
No 26 (27) 7 (29) 19 (27)  
Yes 69 (73) 17 (71) 52 (73) <.820 
Intranasal/smoke 
methamphetamine 
    
Never 86 (91) 22 (92) 64 (90)  
Ever 9 (9) 2 (8) 7 (10) <.999 
Ecstasy use     
Never 76 (80) 23 (96) 53 (75)  
Ever 19 (20) 1 (4) 18 (25) <.036 
Injection drug use†     
No 71 (75) 21 (88) 50 (70)  
Yes 24 (25) 3 (12) 21 (30) <.097 
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Prior research suggests that it is possible that the HIV-seropositive individuals
may have known about their HIV status for some time and have since reduced high-
risk behaviors.29–31 Two characteristics of the study population and design provide
support for earlier HIV diagnoses. First, three fourths of HIV-seropositive MSM
reported having been previously diagnosed with HIV at study entry and in this
study, risk classification was based on recent behavior and not necessarily behavior
preceding HIV acquisition and/or receiving an HIV-seropositive result. In addition,
HIV-seropositive MSM tended to be older than seronegative MSM which may fur-
ther indicate a longer history of known HIV-seropositive status.29,32 In support of
this claim, several studies have reported that younger MSM of color, including
TABLE 3. Sex partner characteristics and behaviors associated with HIV-seropositive status 
among young adult heroin-, crack-, and/or cocaine-using men who have sex with men 
(MSM) in New York City, 2000–2003 
*Median number of sex partners during past 2 months was used to dichotomize number of sex partners.
†Measured among sexually active participants only.
‡Casual partnerships also included partners who exchanged sex for drugs.
§Participants who answered either “no” or “don’t know” were categorized as “no.”
Sex partner characteristics 
and behaviors 
Total (N =95) 
[n (%)] 
HIV seropositive 
(N =24) [n (%)] 
HIV seronegative 
(N =73) [n (%)] 
Fisher’s exact 
P value 
Number of sex partners*     
<3 40 (42) 15 (62) 25 (35)  
≥3 55 (58) 9 (38) 46 (65) <.020 
Any condom use†     
No 32 (38) 8 (40) 24 (38)  
Yes 52 (62) 12 (60) 40 (62) <.999 
Sexual partner characteristics     
No sex 11 (12) 4 (17) 7 (10)  
Steady partner only 14 (15) 7 (29) 7 (10)  
Casual partner only‡ 22 (24) 6 (25) 16 (23)  
Both partner types 46 (49) 7 (29) 39 (57) <.055 
Any female partners     
No 48 (51) 22 (92) 26 (37)  
Yes 47 (49) 2 (8) 45 (63) <.001 
IDU sex partner     
No 74 (78) 21 (88) 53 (75)  
Yes 21 (22) 3 (12) 18 (25) <.190 
Non-IDU sex partner     
No 31 (33) 9 (37) 22 (31)  
Yes 64 (67) 15 (63) 49 (69) <.557 
Known HIV-seropositive 
sex partner§ 
    
No 85 (89) 16 (67) 69 (97)  
Yes 10 (11) 8 (33) 2 (3) <.001 
Exchange sex for money/
drugs partner 
    
No 33 (35) 14 (58) 19 (27)  
Yes 62 (65) 10 (42) 52 (71) <.006 
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drug-using MSM, tend to be at higher risk for HIV and to engage in higher sexual
risk behaviors.9,18,27,32–36 
In addition to reporting lower sexual risk, HIV seropositives reported, surprisingly,
a higher level of socioeconomic status. Specifically, HIV-seropositive MSM were
significantly less likely to be homeless and tended not to use illegal means for
income/survival compared with seronegative MSM. Nearly two thirds of the HIV-
seropositive group had at least completed high school compared with less than half
of the HIV-seronegative MSM. This level of education among a street-recruited
illicit drug-using population was higher than that observed in other similar HIV-study
populations, including the few conducted among heroin- and/or cocaine-using
MSM.10,37,38 An explanation for these findings is the possibility that this population of
HIV-seropositive MSM were less marginalized and more stable compared with the
seronegative comparison group. It is plausible that HIV-seropositive MSM had earlier
and better access to HIV care and counseling and had since reduced risk behaviors. In
support of this assertion, a higher proportion of HIV-seropositive MSM were on
Medicare (92%), had seen the same health care provider for the past 2 years (46%),
and had been seen in a doctor’s office or clinic as opposed to an emergency depart-
ment (75%) compared with HIV seronegatives (66%, 24%, and 31%, respectively).
Several studies have suggested that MSM of color are less likely to disclose their
sexual identity to female sex partners39,40 indicating an increased HIV risk of hetero-
sexual transmission from MSM of color to their female sex partners. High-risk sexual
behaviors have been reported by black MSM who also report sex with women,40–42
particularly among MSM who have not disclosed their sexual history to their
female partners.43 Assessing disclosure of sexual identity or HIV status was not pos-
sible for this analysis; however, a very small proportion of HIV-seropositive MSM
reported sex with female partners. Decisions on female sexual partnerships among
black and Hispanic MSM may differ from white MSM for many reasons, such as
racial/ethnic or cultural differences with regard to images of masculinity; differing
social contexts, expectations, and norms; and fear of stigma and social discrimina-
tion associated with sexual identity and race/ethnicity.40,44–46 Further study is needed
to understand partnership dynamics among MSM of color, with particular atten-
tion to how race/ethnicity, cultural factors, social norms, HIV serostatus, and HIV
disclosure may affect sexual risk behavior among drug-using/nonusing MSM who
also have sex with women. 
Having a recent HIV-seropositive partner was more common among HIV
seropositives than seronegatives. At first glance, this could be considered an
extremely high-risk practice. Given the cross-sectional design of the study, it is
uncertain whether a sexual partnership with an HIV-seropositive person existed
prior to acquiring HIV or after. Sexual partnerships were measured over the past 2
months. Previous reports have suggested that HIV-seropositive MSM may seek
partnerships with known HIV-seropositive individuals.47 This finding highlights the
importance of examining the social context in which certain types of partnerships
occur to fully understand sexual risk taking and protective behaviors. 
There are limitations to this study, including the small sample size. The street-
recruitment methods used resulted in a relatively sizeable number of black and His-
panic drug-using MSM; however, the absolute sample size was small. This may be,
in part, a consequence of targeting both young noninjection drug users and injection
drug users with less specific attention to enrolling MSM. Peer-driven or social network-
based methods could be combined with street outreach to recruit a larger sample of
illicit drug-using MSM for future studies of this type.48,49 As noted earlier, temporal
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relationships between HIV exposure, seroconversion, and HIV-seropositive status
could not be determined in this study because of its cross-sectional design. The
observed inverse association between HIV-seropositive status and sexual risk
behaviors may be due in part to the older age of HIV-seropositive individuals com-
pared with seronegative comparison group. Larger prospective cohort studies with
this population are feasible8,23 and would help to elucidate these findings. 
This study has identified a high-risk subgroup of MSM who remain burdened
with HIV disease and poorly understood. Although the findings are limited, they
suggest that a vulnerable subgroup of drug-using MSM, who may not necessarily
self-identify as being MSM, may be systematically missed in HIV research that
targets more mainstream gay-identified venues or more socially integrated drug-
using MSM. Most HIV research with MSM has involved either illicit drug users or
more mainstream MSM who self-identify as being gay; both may underrepresent
groups of hard-to-reach or “hidden” drug-using MSM. Recruitment efforts need to
be expanded, for example, by using peer- and network-based outreach techniques,
to bolster study enrollment.48,49 Such efforts will ultimately help us to replicate these
preliminary findings and to use them for improving intervention strategies that
reach this elusive population. 
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